Brexpiprazole for schizophrenia and as adjunct for major depressive disorder
Por um escritor misterioso
Descrição
A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder, Acta Neuropsychiatrica
Table 1 from Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder
Brexpiprazole - Mechanism of Action and Clinical Application
Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies - ScienceDirect
Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia - Clinical Trials Arena
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open
Brexpiprazole: Most Up-to-Date Encyclopedia, News & Reviews
Full article: Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder - Document - Gale Academic OneFile
PDF) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study
Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data - ScienceDirect
Unipolar depression in adults: Choosing treatment for resistant depression - UpToDate
Spotlight on brexpiprazole and its potential in the treatment of schiz
de
por adulto (o preço varia de acordo com o tamanho do grupo)
